Posted by Michael Wonder on 31 Jan 2022
Schedule of Pharmaceutical Benefits - 1 February 2022 update
1 February 2022 - The February 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The February issue of the Schedule includes a few revised listings:
- Acalabrutinib (Calquence) - new indication
- Bortezomib (DBL Bortezomib) - new formulation
- Glatiramer acetate (Glatira) - new formulation
- Levothyroxine sodium (thyroxine sodium) (Eltroxin) - new formulation
- Upadacitinib monohydrate (Rinvoq) - new indication
